Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Proof of Concept, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Subjects With Nonalcoholic Steatohepatitis (NASH)

Next Previous
Trial Profile

A Proof of Concept, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Subjects With Nonalcoholic Steatohepatitis (NASH)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 25 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 16 Apr 2022 Results assessing safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis, published in the Journal of Hepatology
  • 15 Nov 2021 Results assessing the changes in CK18 M30 following 24-week treatment with semaglutide (SEMA) alone or in combination with the FXR-agonist cilofexor (CILO) and/or the ACC inhibitor firsocostat , presented at The Liver Meeting 2021: 72nd Annual Meeting of the American Association for the Study of Liver Diseases.
  • 26 Jun 2021 Results evaluating the effects of the glucagon-like peptide-1 receptor agonist semaglutide (sema), alone or in combination with the farnesoid X receptor agonist cilofexor (CILO) and/or the acetyl-CoA carboxylase inhibitor firsocostat (FIR) on FAST presented at The International Liver Congress 2021

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top